Advertisement


Andrew D. Seidman, MD, and Meredith M. Regan, ScD, on Breast Cancer: Results From the TEXT and SOFT Trials

2018 ASCO Annual Meeting

Advertisement

Andrew D. Seidman, MD, of Memorial Sloan Kettering Cancer Center, and Meredith M. Regan, ScD, of Dana-Farber Cancer Institute, discuss study findings on absolute improvements in freedom from distant recurrence with adjuvant endocrine therapies for premenopausal women with hormone receptor–positive, HER2-negative breast cancer (Abstract 503).



Related Videos

Lymphoma
Immunotherapy

Nathan Hale Fowler, MD, and Julie M. Vose, MD, MBA, on Follicular Lymphoma: Results From the RELEVANCE Trial

Julie M. Vose, MD, MBA, of the University of Nebraska Medical Center, and Nathan Hale Fowler, MD, of The University of Texas MD Anderson Cancer Center, discuss phase III study findings on lenalidomide plus rituximab vs chemotherapy plus rituximab, followed by rituximab maintenance, in patients with previously untreated follicular lymphoma (Abstract 7500).

Prostate Cancer

Daniel J. George, MD, on Prostate Cancer: Outcomes for Black and White Patients

Daniel J. George, MD, of Duke University, discusses findings from a multicenter study of black and white patients with metastatic castrate-resistant prostate cancer treated with abiraterone acetate and prednisone (Abstract LBA5009).

Symptom Management

Ryan D. Nipp, MD, on Electronic Symptom Monitoring: Trial Results

Ryan D. Nipp, MD, of Massachusetts General Hospital, discusses study findings on electronic symptom monitoring vs usual care to assess whether the intervention, tested in hospitalized patients with advanced cancer, can improve symptom burden and reduce the risk of readmission (Abstract 10005).

Leukemia

William G. Wierda, MD, PhD, and Julie M. Vose, MD, MBA, on CLL: Results From the CAPTIVATE Trial

Julie M. Vose, MD, MBA, of the University of Nebraska Medical Center, and William G. Wierda, MD, PhD, of The University of Texas MD Anderson Cancer Center, discuss phase II findings on ibrutinib plus venetoclax in first-line treatment of chronic lymphocytic leukemia (Abstract 7502).

Pancreatic Cancer

Thierry Conroy, MD, on Pancreatic Cancer: Results From the PRODIGE 24 Trial

Thierry Conroy, MD, of the Institut de Cancérologie de Lorraine, discusses phase III study findings on adjuvant mFOLFIRINOX vs gemcitabine in patients with resected pancreatic ductal adenocarcinomas (Abstract LBA4001).

Advertisement

Advertisement




Advertisement